Eargo, Inc.

Report azionario NasdaqGS:EAR

Capitalizzazione di mercato: US$53.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Eargo Crescita futura

Criteri Future verificati 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Eargo.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.1%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

None

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Aug 30

Eargo: Straining To Be Heard

Summary Today, we take our first look at a small medical device company called Eargo, Inc. whose stock has slumped 90% over the past year. A good portion of the decline was caused by two key issues, both of which company management is hoping to put in the rearview mirror. An investment analysis follows in the paragraphs below. The art of conversation is the art of hearing as well as of being heard."― William Hazlitt Today, we put Eargo, Inc.(EAR) in the spotlight for the first time. This company has a variety of issues recently that have caused the stock to nosedive deep into 'Busted IPO' territory. Are brighter times on the horizon? An analysis follows below. Seeking Alpha Company Overview: Eargo, Inc. is a small medical device maker headquartered in San Jose, CA. The company markets and sells hearing aids through direct-to-consumer and through omni-channels. The stock currently has an approximate market capitalization of $75 million. The company launched the latest version of its hearing aid line, the Eargo 6 in January of this year. The Eargo 6 is an FDA Class II exempt hearing device featuring Sound Adjust technology that automatically optimizes the soundscape as the user moves between environments. June Company Presentation The company has been dogged by two major issues since it went public. The first was a criminal investigation initiated by the U.S. Department of Justice related to insurance reimbursement claims submitted by the company on behalf of its customers covered by the Federal Employee Health Benefits (FEHB) program. Management denied wrongdoing but settled this issue for $34.4 million in the Spring of this year. June Company Presentation Eargo also no longer accepted insurance as a method of direct payment in late 2021. In the second quarter of this year, Eargo operated on a cash-pay only basis which tanked sales (see section below). The company did get some very good news on this front two weeks ago as the FDA disclosed it would allow the sale of some hearing aids over the counter beginning in October. June Company Presentation The company has shipped over 110,000 hearing aid devices in its history and believes the market is significantly underpenetrated especially for its in-ear devices that offer several advantages to traditional hearing aids. June Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. The company had a GAAP loss of 78 cents a share as revenues plunged nearly 70% on a year-over-year basis to $7.25 million. Both top and bottom lines missed expectations badly. Returns rose to a third of sales from just less than a quarter in the same period a year ago. GAAP gross margin was 34.7%, compared to 71.8% in 2Q2021. Management stated via its earnings press release, the company would be focused on four key areas going forward. Eargo's omni-channel growth strategy Potentially regaining insurance coverage of Eargo for government employees under the FEHB program Refining and expanding the company's physical retail strategy Optimize the cash-pay business while continuing to invest in innovation. June Company Presentation Analyst Commentary & Balance Sheet: Wells Fargo ($10 price target), JPMorgan ($11 price target) and William Blair either maintained or downgraded Eargo to a Hold in the fourth quarter of 2021, but no analyst firms I can find have issued any ratings on Eargo so far in 2022. Just over one out of every ten shares are currently held short. Two insiders sold just over $40,000 in aggregate earlier this month. Another insider sold less than $15,000 worth of equity in March. That has been the only insider activity in Eargo's shares so far in 2022. The company ended the second quarter of the year with just over $106 million in cash and marketable securities on its balance sheet. This is almost entirely due to an issuance of $100 million senior secured convertible notes that occurred late in June. This is the core tranche of a $125 million strategic investment from Patient Square Capital. $16.2 million of these proceeds were used to pay off a previous debt obligation. Management will seek stockholder approval to increase the number of authorized shares and issue full potential amount of note conversion shares at its annual meeting in October of this year. If approved, this will consist of new shares of common stock created by a rights offering.
Seeking Alpha • Aug 16

Eargo jumps 77% following FDA rule on OTC hearing aids

Microcap Eargo (NASDAQ:EAR) closed up 77% on Tuesday following the U.S. FDA's announcement that it would allow the sale of some hearing aids over the counter beginning in October. Average daily volume for the company is ~4.2M shares. ~31.8M shares traded hands on Tuesday. Seeking Alpha's Quant Rating views Eargo (EAR) as a strong sell.
Seeking Alpha • Aug 08

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Eargo press release (NASDAQ:EAR): Q2 Non-GAAP EPS of -$0.78 misses by $0.55. Revenue of $7.25M (-68.3% Y/Y) misses by $21.05M.
Seeking Alpha • Jul 05

Eargo completes $100M senior secured convertible notes issuance

Medical device company Eargo (NASDAQ:EAR) completed the issuance of $100M senior secured convertible notes to Patient Square Capital on Jun. 28. ~$16.3M of the net proceeds was used to repay all existing third-party indebtedness and related pay-off expenses. The remaining proceeds are intended to be used for working capital purposes and to fund general business requirements. Source: Press Release
Seeking Alpha • Dec 30

Eargo: A Binary Play On Hearing Loss

Eargo has exhibited stupendous sales growth in recent years and that looks set to continue. But this growth comes at the cost of significant cash outflows that have largely increased over time. The company's value is implied to be very small at this time, which could lead to significant upside if things go right. But significant risks definitely exist, making the company a binary prospect currently.
Seeking Alpha • Oct 08

Eargo Is A High Risk 'Option' With High Potential

Eargo Inc. is a US-based small-cap public company that manufactures and distributes Completely-In-Canal (CIC) hearing aids throughout the country. The company will be one of the beneficiaries of promoting sales of OTC hearing aids in the United States. Eargo Inc. has created a highly competitive product that meets high-quality standards at an affordable price.
Articolo di analisi • Jul 10

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

In this article we are going to estimate the intrinsic value of Eargo, Inc. ( NASDAQ:EAR ) by estimating the company's...
Articolo di analisi • Jan 16

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

If you want to know who really controls Eargo, Inc. ( NASDAQ:EAR ), then you'll have to look at the makeup of its share...

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Eargo non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:EAR - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
9/30/202341-108-76-75N/A
6/30/202341-141-76-75N/A
3/31/202340-149-121-118N/A
12/31/202237-157-120-117N/A
9/30/202234-159-145-142N/A
6/30/20224-188-154-150N/A
3/31/202219-175-114-109N/A
12/31/202132-158-103-98N/A
9/30/202144-124-65-59N/A
6/30/202185-45-47-41N/A
3/31/202179-32-31-26N/A
12/31/202069-30-31-26N/A
9/30/202057-32-35-30N/A
6/30/202047-44-40-36N/A
3/31/202038-47-43-39N/A
12/31/201933-44-43-39N/A
9/30/201930-42-41-37N/A
12/31/201823-34-30-27N/A
12/31/20177-25-15-14N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista EAR è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di EAR cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di EAR cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di EAR cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di EAR cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di EAR è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/02/20 09:02
Prezzo dell'azione a fine giornata2024/02/20 00:00
Utili2023/09/30
Utili annuali2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Eargo, Inc. è coperta da 4 analisti. di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Robert HopkinsBofA Global Research
Robert MarcusJ.P. Morgan
Lawrence BiegelsenWells Fargo Securities, LLC